Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing therapeutics for large-market and orphan indications targeting inflammation and complement-mediated diseases.
Together with its marketed ophthalmic drug OMIDRIA®, leading Omeros’ pipeline is OMS721, a fully human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the complement system’s lectin pathway.
Phase 3 clinical programs with OMS721 are ongoing in IgA nephropathy (IgAN), hematopoietic stem cell-associated thrombotic microangiopathy (HSCT-TMA), and atypical hemolytic-uremic syndrome (sHUS).
The FDA recently granted OMS721 breakthrough therapy designations for IgAN and HSCT-TMA.